

Isosterism and Molecular Modification in Drug Design

By C. W. Thornber

IMPERIAL CHEMICAL INDUSTRIES LIMITED, PHARMACEUTICALS
DIVISION, MERESIDE, ALDERLEY PARK, MACCLESFIELD,
CHESHIRE, SK10 4TG

1 Introduction

The idea of isosterism goes back to Langmuir¹ in 1919. At that time the word isosterism was used to describe the similarity of molecules or ions which have the same number of atoms and valence electrons *e.g.* O²⁻, F⁻, Ne. Clearly only those isosteres with the same nett charge show similar chemical and physical properties. Grimm² enunciated his hydride displacement law to describe the similarity between groups which have the same number of valence electrons but different numbers of atoms. For example some similarities are present in the sequence: CH₃, NH₂, OH, Hal.

Grimm's hydride displacement law points out some similarities of size in groupings based on elements in the same row of the periodic table. Other similarities to be found in the periodic table are within the groups, where chemical reactivities are similar but with electronegativity decreasing as atomic weight increases and lipophilicity and polarizability increasing with the size of the atom. Other relationships exist in diagonal lines across the periodic table where atoms of similar electronegativity such as nitrogen and sulphur, oxygen and chlorine are found.

In trying to relate biological properties to the physical and chemical properties of atoms, groups, or molecules, many physical and chemical parameters may be involved and the simple relationships mentioned above are clearly inadequate for this purpose. Friedman³ introduced the term 'bioisosterism' to describe the phenomenon in which compounds which are related in structure have similar or antagonistic properties. The use of the word isosterism has clearly outgrown its original meaning when used in medicinal chemistry and a loose flexible definition could be adopted such as: 'Bioisosteres are groups or molecules which have chemical and physical similarities producing broadly similar biological properties'.

The term non-classical isosterism is also used interchangeably with bioisosterism, particularly in connection with isosteres which do not have the same number of atoms but do produce a similarity in some key parameter of importance in


¹ I. Langmuir, *J. Amer. Chem. Soc.*, 1919, **41**, 868, 1543.

² H. G. Grimm, *Z. Elektrochem.*, 1925, **31**, 474; 1928, **34**, 430; 1934, **47**, 53, 594.

³ H. L. Friedman, 'Influence of Isosteric Replacements upon Biological Activity', National Academy of Sciences—National Research Council Publication No. 206. Washington D.C., 1951, p. 295.



Isosterism and Molecular Modification in Drug Design

that series. For example⁴ the two β -adrenergic stimulants compounds (1) and (2) have similar activity.



The concept of bioisosterism has been described in reviews by Burger,^{5a} Schatz,^{5b} Foye,⁶ Korolkovas,⁷ Ariens,⁸ and Hansch.⁹ This present review collates and extends the earlier observations with more recent reports from the literature and suggests new techniques for exploiting the concept.

The 'classical' isosteres as defined by Burger⁵ and Korolkovas⁷ are given in Table 1.

Table 11) *Univalent atoms and groups*2) *Bivalent atoms and groups*3) *Tervalent atoms and groups*4) *Quadrivalent atoms*5) *Ring equivalents*

⁴ A. A. Larson and P. M. Lish, *Nature*, 1964, 203, 1283.

^{5a} A. Burger in 'Medicinal Chemistry' 3rd Edn., ed. A. Burger, Wiley-Interscience, New York, 1970.

^{5b} V. B. Schatz in 'Medicinal Chemistry' 2nd Edn., ed. A. Burger, Wiley-Interscience, New York, 1960.

⁶ W. O. Foye, 'Principles of Medicinal Chemistry', Lea and Febiger, Philadelphia, 1970.

⁷ A. Korolkovas, 'Essentials of Molecular Pharmacology: Background for Drug Design', Wiley, 1970.

⁸ E. J. Ariens in 'Drug Design', ed. E. J. Ariens, Academic Press, New York, 1971, Vol. 1.

[View Article Online](#)

C. W. Thornber

2 Bioisosterism in Molecular Modification

In the process of developing a lead compound, an antagonist to a known agonist, or an anti-metabolite from a known substrate, a large number of systematic molecular modifications will be made. The modern concept of bioisosterism can be an aid to the design of such modifications. In making a bioisosteric replacement the following parameters of the group being changed could be considered:

- (a) Size.
- (b) Shape (bond angles, hybridization).
- (c) Electronic distribution (polarizability, inductive effects, charge, dipoles).
- (d) Lipid solubility.
- (e) Water solubility.
- (f) pK_a .
- (g) Chemical reactivity (including likelihood of metabolism).
- (h) Hydrogen bonding capacity.

It is unlikely that any bioisosteric replacement will leave all these parameters undisturbed. The extent to which the replacement is useful will depend upon which of these parameters is important and which ones the bioisostere can best mimic.

The element of a molecule being modified may have one or more of the following roles.

- (i) *Structural*. If the moiety has a structural role in holding other functionalities in a particular geometry, parameters such as size and bond angle will be important. The moiety may be buried deep in the molecule and have little contact with the external medium.
- (ii) *Receptor interactions*. If the moiety to be replaced is concerned with a specific interaction with a receptor or enzyme its size, shape, electronic properties, pK_a , chemical reactivity, and hydrogen bonding will be the important parameters.
- (iii) *Pharmacokinetics*. The moiety to be replaced may be necessary for the absorption, transport, and excretion of the compound. In this case lipophilicity, hydrophilicity, hydrogen bonding, and pK_a are likely to be important.
- (iv) *Metabolism*. The moiety may be involved in blocking or aiding metabolism. In this case chemical reactivity will be an important parameter. For example chloro and methyl substituents on a benzene ring may be interchangeable for certain purposes but the toluene derivative can be metabolized to a benzoic acid and may therefore have a shorter half-life or unexpected side effects.

Usually one will not know which role(s) the various parts of the molecule play(s) in its action and this determination will be part of the structure-activity study. However, from the simple considerations listed above it is clear that:-

Isosterism and Molecular Modification in Drug Design

(A) A given molecular modification may allow some, but probably not all of the parameters (a)—(h) to be kept the same.

(B) Whether the same or a different biological activity results from the replacement will be governed by the role(s) which that moiety fulfils in the molecule and whether parameters affecting that role have been disturbed.

(C) From (A) and (B) it follows that what proves to be a good bioisosteric replacement in one series of compounds will not necessarily be useful in another.

Completely identical properties are rarely sought and will in any case be difficult if not impossible to achieve. What we are more likely to be seeking is a subtle change in the molecule which will leave some properties the same and some different in order to improve potency, selectivity, absorption, duration, and toxicity. Bioisosteric replacements allow molecular modifications, in which the number of variables changed are limited. Ariens⁸ and Korolkovas⁷ have tried to introduce the idea of partial bioisosteric groups as those which turn an agonist into an antagonist. Although their lists of groups may be suggestive to the drug designer, the idea is probably incorrect because of the statement (C) above. An 'antagonist' group in one molecule will only antagonize a similar 'agonist' group in another molecule if the agonist groups in both series are performing the same function. If an isosteric replacement results in a molecule which has some properties similar to the parent molecule but some important property has changed, it may be possible to compensate for this undesirable change by modifications elsewhere in the molecule. For example a molecular modification may reduce the lipid solubility of the molecule thereby affecting its absorption, transport, and apparent potency. Optimum activity may be regained by inserting lipophilic groups into the molecule at some sterically undemanding site. Consequently the best compounds in this parallel series of isosteres, such as for example furans and thiophens, are likely to have different substituent patterns.

3 The Mathematical Formulation

The arguments used above can be expressed in the mathematical form used by Hansch¹⁰ for the case where a simple substituent is being varied, for example on a benzene ring. If the potency of a drug is a function of several parameters of the substituent then:

$$\log \frac{1}{c} = A(\pi) + B(\sigma) + C(E_s)$$

where Hansch's π value is used for the lipophilic character, Hammett's σ value for the electronic property, Taft's steric parameter to denote the size of the group and c is the concentration of drug required to achieve a given effect.

If such a relationship were found for a drug series in which the constants B and C were zero then the potency would be a function of π only. In this context groups would be bioisosteric if they have similar π values independent of their

¹⁰ C. Hansch, *Accounts Chem. Res.*, 1969, 2, 232.

C. W. Thornber

σ and E_s values. If however the three constants A , B , and C are all significant a much more limited range of equivalent groups will be available.

If a series of compounds has more than one property, as is usual, then more than one equation will be needed to describe the effects of changing the substituent:

$$\log \frac{1}{c} = A(\pi) + B(\sigma) + C(E_s)$$

Desired activity

$$\log \frac{1}{c} = D(\pi) + E(\sigma) + F(E_s)$$

Side effects

Clearly if $A = D$, $B = E$, and $C = F$, etc., no selectivity can be found within this limited series. If however $C \ll F$ then for the desired activity E_s is not important and π and σ may be optimized while reducing the value of E_s , thereby reducing the side effects. This phenomenon of increasing selectivity by bioisosteric replacement relies upon the fact that some desirable properties in the molecule can be retained when unimportant parameters can be varied. An unimportant parameter for the biological activity desired may be a key parameter in the side effect.

Thus bioisosteric replacements are useful in searching for potency, selectivity, absorption, and duration. Following the Hansch treatment one could produce a modern definition of bioisosterism based upon measurable parameters such as π , σ , E_s , hydrogen bonding properties, pK_a , etc., and Hansch⁹ has used the term 'isophilic' for groups with the same π value.

Table 2 shows some functional groups with similar electron-withdrawing properties. If electronic effects alone influence the biological activity in a series of drugs then these groups would be equivalent. If, however, the lipophilicity and steric factors are important then absolute identity cannot be achieved.

Table 2

Functional Group	σ_m	π	E_s
F	0.34	0.14	0.78
Cl	0.37	0.71	9.27
Br	0.39	0.86	0.08
I	0.35	1.12	-0.16
CF ₃	0.43	0.88	-1.16
SCF ₃	0.40	1.44	
COMe	0.31	-0.55	
CHO	0.36	-0.65	
CO ₂ Me	0.32	-0.01	
CH=CH-NO ₂	0.32	0.11	

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.